Loading...
XCNQ
ZRO
Market cap2mUSD
May 14, Last price  
0.12CAD
Name

Biosenta Inc

Chart & Performance

D1W1MN
XCNQ:ZRO chart
No data to show
P/E
—
P/S
2,922.24
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.40%
Rev. gr., 5y
-2.24%
Revenues
1k
+32.34%
00000339,78058,367122,87880,48717,1781,16701,530168,1051,1511,0421,379
Net income
-2m
L-64.64%
-77,042-331,972-504,791-845,648-2,324,004-2,282,911-4,449,316-3,528,1602,747,197-1,034,369-1,189,646-545,546-799,561-2,052,118-1,485,348-6,299,754-2,227,678
CFO
-779k
L+41.50%
-84,541-19,35099-765,639-1,087,437-1,290,330-1,832,596-1,218,471-589,110-217,456-225,064-326,731-319,729-672,287-504,433-550,788-779,348
Earnings
Aug 26, 2025

Profile

Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada. It is involved in developing true, an anti-microbial, dual-action disinfectant that kills viruses, bacteria, mold, and germs on contact. The company also intends to manufacture and distribute Tri-Filler, an anti-microbial filler to perform filling and bulking functions. Biosenta Inc. was founded in 1986 and is based in Toronto, Canada.
URL
https://www.biosenta.com/
IPO date
Sep 22, 2005
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
1
32.34%
1
-9.47%
1
-99.32%
Cost of revenue
1,183
1,475
1,209
Unusual Expense (Income)
NOPBT
(1,182)
(1,474)
(1,208)
NOPBT Margin
Operating Taxes
27
Tax Rate
NOPAT
(1,182)
(1,474)
(1,235)
Net income
(2,228)
-64.64%
(6,300)
324.13%
(1,485)
-27.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,100
BB yield
-42.47%
Debt
Debt current
97
323
35
Long-term debt
5,455
5,295
60
Deferred revenue
Other long-term liabilities
(60)
Net debt
5,543
5,613
68
Cash flow
Cash from operating activities
(779)
(551)
(504)
CAPEX
(16)
Cash from investing activities
(16)
Cash from financing activities
782
545
420
FCF
(1,009)
(2,263)
(847)
Balance
Cash
9
6
27
Long term investments
Excess cash
8
6
27
Stockholders' equity
(8,447)
(7,856)
(1,910)
Invested Capital
6,123
5,619
(1,084)
ROIC
264.73%
ROCE
50.86%
65.91%
40.37%
EV
Common stock shares outstanding
28,781
26,147
21,303
Price
0.09
-78.57%
0.42
5.00%
0.40
-24.53%
Market cap
2,590
-76.41%
10,982
28.87%
8,521
-9.66%
EV
8,134
16,595
8,589
EBITDA
(1,179)
(1,474)
(1,208)
EV/EBITDA
Interest
1,135
64
223
Interest/NOPBT